Herbal preparations and “natural” dietary supplements are frequently used by patients with cardiovascular disease – often in the hope of “gently” influencing blood pressure, lipids or symptoms. However, guidelines from European and American professional societies unanimously emphasize that phytotherapeutics and dietary supplements should not replace established lifestyle and pharmacotherapy. In particular, the 2025 focused ESC/EAS update on dyslipidemia therapy concludes, after reviewing the available evidence, that there is insufficient evidence for any supplement that lowers LDL cholesterol while improving cardiovascular risk with reasonable safety.
Autoren
- Tanja Schliebe
Publikation
- PHYTOTHERAPIE PRAXIS
Related Topics
You May Also Like
- Psoriasis: System therapies in everyday practice
Current real-world data at a glance
- Omega-3 fatty acids for obesity and type 2 diabetes
More fish oil for better lipid and HbA1c levels
- MASLD often goes unnoticed and is underestimated
Think tank for improving the supply situation
- DGPPN Congress
People at the center of care
- Diagnostics of respiratory viral infections
What is tested when and on whom?
- Lung cancer
Multidisciplinary teams in oncology
- Seborrheic dermatitis in adults
Do not underestimate the symptom burden
- SGLT2 inhibitors